865PDRANGE, a phase III, randomized, placebo-controlled, double-blind trial of ramucirumab (RAM) and docetaxel (DOC) in platinum-refractory urothelial carcinoma (UC): Overall survival results
2018
Keywords:
-
Correction
-
Source
-
Cite
-
Save
0
References
1
Citations
NaN
KQI